|
Characteristics
|
Mean (min.-max.)
|
SD
|
|---|
|
Age at diagnosis, years
|
55.1 (38–69)
|
7.89
|
|
Education, years
|
15.8 (8–24)
|
3.47
|
|
Postmenopausal, no (%)
|
38 (68 %)
| |
|
Systolic BP, mmHg
|
132 (87–184)
|
22.9
|
|
Diastolic BP, mmHg
|
77.4 (58–108)
|
11.9
|
|
Height, cm
|
167 (155–181)
|
5.97
|
|
Weight, kg
|
70.5 (49–97)
|
11.6
|
|
BMI, kg/m2
|
25.1 (20.0–33.2)
|
3.48
|
|
Statin use, no (%)
|
3 (5 %)
| |
|
Serum lipoproteins
|
|
Cholesterol, mmol/L
|
5.74 (4.00–8.00)
|
1.00
|
|
HDL-cholesterol, mmol/L
|
1.78 (1.00–3.00)
|
0.49
|
|
LDL-cholesterol, mmol/L
|
3.45 (1.31–5.49)
|
0.98
|
|
Triglycerides, mmol/L
|
1.18 (0–3)
|
0.59
|
|
Apolipoprotein-A, mmol/L
|
1.67 (1–3)
|
0.29
|
|
Apolipoprotein-B, mmol/L
|
1.04 (0–2)
|
0.27
|
|
Tumor characteristics
|
|
Tumor diameter, mm
|
16.4 (4–40)
|
8.52
|
|
Grade 1–3
|
1.96 (1–3)
|
0.71
|
|
Ki-67 hotspot, %
|
26.5 (1–81)
|
21.8
|
|
Nodal metastasis, no
|
0,75 (0–11)
|
2.13
|
|
ER positive, no (%)
|
52 (93 %)
| |
|
ER percent
|
88,1 (0–100)
|
26.9
|
|
PgR positive, no (%)
|
46 (82 %)
| |
|
PgR percent
|
64,2 (0–100)
|
36.8
|
|
Hormone receptor negative, no (%)
|
4 (7 %)
| |
|
HER2 positive, no (%)
|
3 (5 %)
| |
-
Abbreviations: BP blood pressure, BMI body mass index, ER estrogen receptor, HER2 human epidermal growth factor 2, HDL high-density lipoprotein, LDL low-density lipoprotein, PgR progesterone receptor, Ki 67 antigen Ki-67. ER positive when ≥ 1 %. PgR positive when ≥ 10 %
